Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aneliya Parvanova

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Plos One|July 17, 2024
GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniquesFabiola Carrara, Flavio Gaspari, Matias Trillini, et al.
Diabetes Care|June 23, 2010
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trialPiero Ruggenenti, Dario Cattaneo, Stefano Rota, et al.
Diabetes Research and Clinical Practice|May 25, 2023
MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and "preserved" kidney function: A cross-sectional studyAneliya Parvanova, Manuela Abbate, Aina Maria Yañez, et al.
Diabetes|June 5, 2013
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapyErica Rurali, Marina Noris, Antonietta Chianca, et al.
Kidney International|March 1, 2013
The GFR and GFR decline cannot be accurately estimated in type 2 diabeticsFlavio Gaspari, Piero Ruggenenti, Esteban Porrini, et al.
Journal of Hypertension|January 19, 2011
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trialPiero Ruggenenti, Anna Fassi, Aneliya Parvanova Ilieva, et al.
Diabetes Care|July 10, 2012
Glomerular hyperfiltration and renal disease progression in type 2 diabetesPiero Ruggenenti, Esteban L Porrini, Flavio Gaspari, et al.
Journal of the American Society of Nephrology : JASN|September 1, 2012
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetesPiero Ruggenenti, Esteban Porrini, Nicola Motterlini, et al.
Frontiers in Genetics|August 21, 2019
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 DiabetesElisabetta Valoti, Marina Noris, Annalisa Perna, et al.
Diabetes Research and Clinical Practice|February 27, 2022
Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial)Piero Ruggenenti, Monica Cortinovis, Matias Trillini, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Plos One|July 17, 2024
GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniquesFabiola Carrara, Flavio Gaspari, Matias Trillini, et al.
Diabetes Care|June 23, 2010
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trialPiero Ruggenenti, Dario Cattaneo, Stefano Rota, et al.
Diabetes Research and Clinical Practice|May 25, 2023
MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and "preserved" kidney function: A cross-sectional studyAneliya Parvanova, Manuela Abbate, Aina Maria Yañez, et al.
Diabetes|June 5, 2013
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapyErica Rurali, Marina Noris, Antonietta Chianca, et al.
Kidney International|March 1, 2013
The GFR and GFR decline cannot be accurately estimated in type 2 diabeticsFlavio Gaspari, Piero Ruggenenti, Esteban Porrini, et al.
Journal of Hypertension|January 19, 2011
Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trialPiero Ruggenenti, Anna Fassi, Aneliya Parvanova Ilieva, et al.
Diabetes Care|July 10, 2012
Glomerular hyperfiltration and renal disease progression in type 2 diabetesPiero Ruggenenti, Esteban L Porrini, Flavio Gaspari, et al.
Journal of the American Society of Nephrology : JASN|September 1, 2012
Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetesPiero Ruggenenti, Esteban Porrini, Nicola Motterlini, et al.
Frontiers in Genetics|August 21, 2019
Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 DiabetesElisabetta Valoti, Marina Noris, Annalisa Perna, et al.
Diabetes Research and Clinical Practice|February 27, 2022
Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial)Piero Ruggenenti, Monica Cortinovis, Matias Trillini, et al.
Pageof 3